Zacks Research Issues Positive Estimate for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities researchers at Zacks Research lifted their Q1 2025 EPS estimates for Halozyme Therapeutics in a note issued to investors on Tuesday, April 29th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $0.88 for the quarter, up from their previous estimate of $0.87. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q2 2025 earnings at $1.09 EPS, Q1 2026 earnings at $1.30 EPS, Q2 2026 earnings at $1.42 EPS, Q3 2026 earnings at $1.56 EPS, FY2026 earnings at $6.00 EPS and FY2027 earnings at $7.39 EPS.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million.

Several other research firms also recently commented on HALO. Benchmark restated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. HC Wainwright reiterated a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Friday, April 25th. Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $62.89.

Halozyme Therapeutics Stock Up 1.9 %

Shares of HALO stock opened at $61.19 on Thursday. Halozyme Therapeutics has a one year low of $39.79 and a one year high of $66.00. The stock has a market cap of $7.56 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock has a fifty day moving average price of $60.79 and a 200 day moving average price of $55.37.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HALO. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC acquired a new position in Halozyme Therapeutics in the fourth quarter valued at $29,000. Bessemer Group Inc. boosted its position in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 207 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 197 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics in the fourth quarter valued at $69,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,697 shares of company stock worth $1,558,052. 2.40% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.